Scorpius (NYSEMKT: HTBX)
Scorpius Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Scorpius Company Info
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
News & Analysis
Why Heat Biologics Stock Is Popping Today
A pre-print is sending the biotech's shares higher today.
Why Heat Biologics, Inovio Pharmaceuticals, and Novavax Are Getting Clobbered Today
Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.
Why Heat Biologics Stock Surged Today
Encouraging early results for the biotech's coronavirus vaccine has investors excited.
Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today
Major new developments in the race for a COVID-19 vaccine is driving investors to reevaluate their positions.
Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today
Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
2 Risky Coronavirus Vaccine Stocks That Could Make You Filthy Rich
Heat Biologics and Vaxart could have a lot more room to run.
Why Heat Biologics Stock Is Spiking Today
The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.